Heat Biologics to Present at Rodman & Renshaw 13th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, NC--(Marketwire - August 29, 2011) -

Heat Biologics (www.heatbio.com), a clinical-stage immunotherapy company, announced today that it will be a presenting company at the Rodman & Renshaw 13th Annual Healthcare Conference, taking place in New York City, Sept. 11-13, 2011.

During his presentation at 4:30 p.m. EDT on Sept. 12, Heat CEO Jeffrey Wolf will provide an update on the company’s novel off-the-shelf “ImPACT” therapeutic vaccines to combat a wide range of cancers and infectious diseases. He will also be available to meet privately with analysts, industry executives and investors during the conference.

“We look forward to this opportunity to showcase the progress Heat is making in its quest to bring to market viable treatments for several of the most deadly cancers and other diseases,” said Wolf. “The Rodman & Renshaw conference is the ideal platform from which to educate on and generate expanded interest in our ImPACT Therapy.”

Heat is preparing to initiate Phase II clinical trials in October with its lead drug, HS-110, for use against non-small cell lung cancer. HS-110 is a vaccine therapy built on Heat’s ImPACT technology, which reprograms live tumor cells to continually pump out antigens that mobilize and activate killer T cells against the targeted cancer. In the case of HS-110, those targets are the abnormal proteins expressed by lung cancer cells.

Those interested in meeting with Wolf during the conference may contact him directly or through the 1x1 Meetings portal on the Rodman & Renshaw conference website at http://www.rodmanandrenshaw.com/conferences?id=162.

About Heat Biologics
Heat Biologics (www.heatbio.com) is a clinical-stage company focused on developing its novel off-the-shelf “ImPACT” therapeutic vaccines to combat a wide range of cancers and infectious diseases. ImPACT Therapy exploits the natural ability of antigens to activate the immune system by utilizing live, off-the-shelf, genetically modified cells injected into a patient to elicit a powerful immune response against the disease target. Heat’s cutting-edge ImPACT Therapy is based upon heat shock protein gp-96, a chaperone protein found in all human cells and normally tethered to our cells with a leash called the KDEL sequence. ImPACT Therapy removes this KDEL leash, thus transforming allogeneic living cells into powerful machines that continually pump out gp96 and their chaperoned antigens to activate the immune system against the full spectrum of antigens expressed by a patient’s disease.

Heat plans to enter Phase IIA trials against non-small cell lung cancer in October. Positive prophylactic and therapeutic data against SIV (the primate equivalent of HIV) is also been generated in a large 48-primate NIH-sponsored study, the first of ImPACT’s ability to combat viral diseases. Heat plans to initiate additional clinical trials against bladder and ovarian cancer in early 2012.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: immunotherapy nsclc lung cancer clinical trials